GKOSGlaukos Corporation
$125.00
$3.31
(2.72%)
Closed $125.00
$1.40
(1.12%)
After Hours
EarningsJul 29
Mkt Cap$7.34B
Vol1.44M
Fundamentals
Mkt Cap
$7.34B
Volume
-
52W High
$148.11
52W Low
$73.16
PE Ratio
-37.98
Avg. Volume
1.11M
EPS (Annual)
-$3.28
Rev/Employee
$463,840.95
Earnings
Jul 29
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Zacks
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...
Business Wire
Insider Selling: Glaukos (NYSE:GKOS) COO Sells 19,573 Shares of Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 19,573 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer...
MarketBeat
Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $140.00, for a total value of $1,400,000.00. Following the completion of the transaction, the chief financial...
MarketBeat
Leana Wen Sells 1,700 Shares of Glaukos (NYSE:GKOS) Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Leana Wen sold 1,700 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the sale, the director directly owned 19,739...
MarketBeat
Vanguard Group Inc. Sells 26,028 Shares of Glaukos Corporation $GKOS
Vanguard Group Inc. decreased its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,020,492 shares of the medical instruments supplier's sto...
MarketBeat
UBS Group AG Increases Position in Glaukos Corporation $GKOS
UBS Group AG raised its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 316.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 873,942 shares of the medical instruments supplier's stock after b...
MarketBeat
Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Glaukos from a "hold" rating to a "buy" rating in a research note on Saturday...
MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock
JPMorgan Chase & Co. increased their price target on Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday...
MarketBeat
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
Zacks
<
1
2
...
>